cyclosporine has been researched along with alpha-Galactosidase A Deficiency in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagovich, M; Binnington, B; Bond, S; De Rosa, M; Lingwood, C; Mattocks, M; Medin, J; Rasaiah, VI | 1 |
| Briggs, JD; dos Santos, JP; Elinder, CG; Jones, EH; Mendel, S; Piccoli, G; Simpson, HK; Tognoni, G; Tsakiris, D; Valderrabano, F; Vanrenterghem, Y | 1 |
2 other study(ies) available for cyclosporine and alpha-Galactosidase A Deficiency
| Article | Year |
|---|---|
Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model.
Topics: alpha-Galactosidase; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cyclosporine; Disease Models, Animal; Fabry Disease; Gaucher Disease; Kidney; Liver; Mice; Trihexosylceramides | 2006 |
Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry.
Topics: Adolescent; Adult; Aged; Cisplatin; Cyclosporine; Europe; Fabry Disease; Female; Humans; Kidney Diseases; Male; Middle Aged; Registries; Renal Replacement Therapy; Scleroderma, Systemic; Survival Rate | 1996 |